Carbapenem-Based Antibiotics Market Report 2026

Carbapenem-Based Antibiotics Market Overview

• Carbapenem-Based Antibiotics market size has reached to $4.78 billion in 2025 • Expected to grow to $6.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Rising Bacterial Infections And The Surge In Demand For Carbapenem-Based Antibiotics Is A Driving Force In Market Expansion • Market Trend: Innovative Product Launches Drive Growth In The Carbapenem-Based Antibiotics Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Carbapenem-Based Antibiotics Market?

Carbapenem-based antibiotics are a class of broad-spectrum antibiotics that are highly effective against many bacterial infections. Carbapenem antibiotics are commonly used to treat severe infections caused by gram-positive and gram-negative bacteria, including some strains resistant to other antibiotics. The main types of carbapenem-based antibiotics are meropenem, imipenem, doripenem, tebipenem, and others. Meropenem is a broad-spectrum antibiotic used to treat a wide range of bacterial infections by inhibiting bacterial cell wall synthesis. Meropenem is used to treat a variety of serious bacterial infections, including pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. The carbapenem-based antibiotics are used to treat intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, gynecologic infections, and others that are sold in hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Carbapenem-Based Antibiotics Market Growth Forecast?

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $6.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to emergence of multidrug-resistant bacteria, development of combination therapies, expansion of healthcare access in emerging markets, adoption of precision medicine approaches, investment in novel carbapenem derivatives. Major trends in the forecast period include rising antibiotic resistance, increasing hospital-acquired infections, expansion of hospital infrastructure, growth in surgical procedures, demand for pediatric and geriatric antibiotics.

Global Carbapenem-Based Antibiotics Market Segmentation

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types 2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use 2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy 3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections 4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections 5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

What Is The Driver Of The Carbapenem-Based Antibiotics Market?

The increasing incidence of bacterial infections is expected to propel the growth of the carbapenem-based antibiotics market going forward. Bacterial infections are infections caused by bacteria, microscopic organisms that can invade the body and cause a range of diseases and symptoms. Carbapenem-based antibiotics treat severe or multidrug-resistant bacterial infections, including those caused by gram-positive and gram-negative bacteria. For instance, in July 2024, according to the report published by the Centers for Disease Control and Prevention, a US-based government agency, during 2023, 78% of all bacterial infections were diagnosed by CIDTs in the historic catchment area, including 46% diagnosed using only CIDTs. Therefore, an increased incidence of bacterial infections drives the growth of the carbapenem-based antibiotics industry.

Key Players In The Global Carbapenem-Based Antibiotics Market

Major companies operating in the carbapenem-based antibiotics market are Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, Teva Pharmaceutical Industries Ltd., Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co. Ltd., ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Global Carbapenem-Based Antibiotics Market Trends and Insights

Major companies operating in the carbapenem-based antibiotics market are innovating financial and distribution models to sustain their market presence and support antibiotic stewardship. Subscription models aim to decouple revenue from volume sold, encouraging responsible use while ensuring profitability for pharmaceutical companies. For instance, in August 2024, the National Health Service (NHS), a UK-based government department, launched a pioneering subscription scheme in collaboration with the pharmaceutical sector to combat antimicrobial resistance (AMR). This innovative model allows drugmakers to receive fixed annual payments, up to $23.12 million (£20 million) per drug regardless of prescription volume, thus removing incentives for overuse. Valued at approximately £1.9 billion over 16 years, the scheme aims to stimulate the development of new antibiotics, including carbapenems, by ensuring financial viability for drug manufacturers. The NHS prioritizes products targeting critical pathogens identified by the World Health Organization, reinforcing its commitment to responsible antibiotic stewardship while fostering innovation in antibiotic development.

What Are Latest Mergers And Acquisitions In The Carbapenem-Based Antibiotics Market?

In July 2023, Melinta Therapeutics LLC, a US-based commercial-stage company that manufacture a carbapenem based antibiotic, partnered with the Biomedical Advanced Research and Development Authority (BARDA), to advance FDA-approved antibiotics. Through this collaboration, BARDA granted $20.5 million in initial funding, with the possibility of increasing support up to $141.9 million if all options are exercised, allowing Melinta to advance four supplemental new drug applications (sNDAs) for expanded indications. Biomedical Advanced Research and Development Authority (BARDA) is a US-based government agency that supports the development of medical countermeasures.

Regional Insights

North America was the largest region in the Carbapenem-Based Antibiotics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Carbapenem-Based Antibiotics Market?

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Carbapenem-Based Antibiotics Market Report 2026?

The carbapenem-based antibiotics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.